Literature DB >> 21091645

Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.

Roger A Sabbadini1.   

Abstract

Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid thought to be dysregulated in a variety of disease conditions. In this review, we discuss the roles of S1P in cancer and in wet age-related macular degeneration. We also explore potential treatment strategies for these disorders, including the utility of anti-S1P antibodies acting as molecular sponges to neutralize dysregulated S1P in relevant tissues.
© 2011 Lpath, Inc.. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21091645      PMCID： PMC3058156          DOI： 10.1111/j.1476-5381.2010.01118.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  122 in total

1.  Antitumor activity of sphingosine kinase inhibitors.

Authors:  Kevin J French; John J Upson; Staci N Keller; Yan Zhuang; Jong K Yun; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2006-04-21       Impact factor: 4.030

2.  Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.

Authors:  Kenneth LaMontagne; Amanda Littlewood-Evans; Christian Schnell; Terence O'Reilly; Lorenza Wyder; Teresa Sanchez; Beatrice Probst; Jeannene Butler; Alexander Wood; Gene Liau; Eric Billy; Andreas Theuer; Timothy Hla; Jeanette Wood
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

Review 3.  Sphingosine kinase: biochemical and cellular regulation and role in disease.

Authors:  Tarek Assad Taha; Yusuf Awni Hannun; Lina Marie Obeid
Journal:  J Biochem Mol Biol       Date:  2006-03-31

Review 4.  Emerging medicinal roles for lysophospholipid signaling.

Authors:  Shannon E Gardell; Adrienne E Dubin; Jerold Chun
Journal:  Trends Mol Med       Date:  2006-01-10       Impact factor: 11.951

5.  Sphingosine kinase 1 is up-regulated in colon carcinogenesis.

Authors:  Toshihiko Kawamori; Walid Osta; Korey R Johnson; Benjamin J Pettus; Jacek Bielawski; Takuji Tanaka; Michael J Wargovich; Bandaru S Reddy; Yusuf A Hannun; Lina M Obeid; Daohong Zhou
Journal:  FASEB J       Date:  2005-11-30       Impact factor: 5.191

6.  Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H.

Authors:  Nalini S Bora; Sankaranarayanan Kaliappan; Purushottam Jha; Qin Xu; Jeong-Hyeon Sohn; Dhara B Dhaulakhandi; Henry J Kaplan; Puran S Bora
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

Review 7.  Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics.

Authors:  Sheldon Milstien; Sarah Spiegel
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages.

Authors:  Barbara Visentin; John A Vekich; Bradley J Sibbald; Amy L Cavalli; Kelli M Moreno; Rosalia G Matteo; William A Garland; Yiling Lu; Shuangxing Yu; Hassan S Hall; Vikas Kundra; Gordon B Mills; Roger A Sabbadini
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

9.  Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.

Authors:  Jeffrey S Heier; Andrew N Antoszyk; Peter Reed Pavan; Steven R Leff; Philip J Rosenfeld; Thomas A Ciulla; Richard F Dreyer; Ronald C Gentile; Judy P Sy; Gary Hantsbarger; Naveed Shams
Journal:  Ophthalmology       Date:  2006-02-14       Impact factor: 12.079

Review 10.  Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases.

Authors:  Y Yatomi
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116
View more
  38 in total

Review 1.  Shaping the landscape: metabolic regulation of S1P gradients.

Authors:  Ana Olivera; Maria Laura Allende; Richard L Proia
Journal:  Biochim Biophys Acta       Date:  2012-06-23

2.  Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

Authors:  Leyre Brizuela; Claire Martin; Pauline Jeannot; Isabelle Ader; Cécile Gstalder; Guillaume Andrieu; Magalie Bocquet; Jean-Michel Laffosse; Anne Gomez-Brouchet; Bernard Malavaud; Roger A Sabbadini; Olivier Cuvillier
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

3.  Pericyte-derived sphingosine 1-phosphate induces the expression of adhesion proteins and modulates the retinal endothelial cell barrier.

Authors:  Paul G McGuire; Sampathkumar Rangasamy; Joann Maestas; Arup Das
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-09-22       Impact factor: 8.311

Review 4.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

5.  Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde.

Authors:  Noriko Takuwa; Wa Du; Erika Kaneko; Yasuo Okamoto; Kazuaki Yoshioka; Yoh Takuwa
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

6.  Sphingosine-1-phosphate (S1P) Receptor Modulators Provide Potential for Diverse Treatments.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2013-09-19       Impact factor: 4.345

7.  Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer.

Authors:  Liang Zhang; Xiaoen Wang; Andrea J Bullock; Marcella Callea; Harleen Shah; Jiaxi Song; Kelli Moreno; Barbara Visentin; Douglas Deutschman; David C Alsop; Michael B Atkins; James W Mier; Sabina Signoretti; Manoj Bhasin; Roger A Sabbadini; Rupal S Bhatt
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

Review 8.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

9.  Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy.

Authors:  Gabriela Schneider; Ewa Bryndza; Ahmed Abdel-Latif; Janina Ratajczak; Magdalena Maj; Maciej Tarnowski; Yuri M Klyachkin; Peter Houghton; Andrew J Morris; Axel Vater; Sven Klussmann; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2013-04-24       Impact factor: 5.852

10.  S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma.

Authors:  Yong Liu; Jiehui Deng; Lin Wang; Heehyoung Lee; Brian Armstrong; Anna Scuto; Claudia Kowolik; Lawrence M Weiss; Stephen Forman; Hua Yu
Journal:  Blood       Date:  2012-06-28       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.